A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group Study (E2392)

Richard Hellman; Donna S. Neuberg; Henry Wagner; Margaret Grunnet; H. Ian Robins; Daniel Karp; Patrick Flynn; George Adams

doi:10.1023/A:1005867520788

A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group Study (E2392)

Richard Hellman, Donna S. Neuberg, Henry Wagner, Margaret Grunnet, H. Ian Robins, Daniel Karp, Patrick Flynn, George Adams

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas. Thirty three patients (median age 51 years) were entered (27 with glioblastoma multiforme, 6 with anaplastic astrocytoma). Toxicity was manageable with no lethal toxicities. Five of seven life threatening toxicities were hematologic. Median overall survival was 14.2 months. These data suggest this regimen is effective treatment for patients with high grade gliomas.

Original language	English (US)
Pages (from-to)	55-62
Number of pages	8
Journal	Journal of neuro-oncology
Volume	37
Issue number	1
DOIs	https://doi.org/10.1023/A:1005867520788
State	Published - Feb 25 1998

All Science Journal Classification (ASJC) codes

Oncology
Neurology
Clinical Neurology
Cancer Research

Access to Document

10.1023/A:1005867520788

Fingerprint Dive into the research topics of 'A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group Study (E2392)'. Together they form a unique fingerprint.

Cite this

Hellman, R., Neuberg, D. S., Wagner, H., Grunnet, M., Robins, H. I., Karp, D., Flynn, P., & Adams, G. (1998). A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group Study (E2392). Journal of neuro-oncology, 37(1), 55-62. https://doi.org/10.1023/A:1005867520788

Hellman, Richard ; Neuberg, Donna S. ; Wagner, Henry ; Grunnet, Margaret ; Robins, H. Ian ; Karp, Daniel ; Flynn, Patrick ; Adams, George. / A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group Study (E2392). In: Journal of neuro-oncology. 1998 ; Vol. 37, No. 1. pp. 55-62.

@article{8e57b168c0834ae2b5913a884a0e2472,

title = "A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group Study (E2392)",

abstract = "This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas. Thirty three patients (median age 51 years) were entered (27 with glioblastoma multiforme, 6 with anaplastic astrocytoma). Toxicity was manageable with no lethal toxicities. Five of seven life threatening toxicities were hematologic. Median overall survival was 14.2 months. These data suggest this regimen is effective treatment for patients with high grade gliomas.",

author = "Richard Hellman and Neuberg, {Donna S.} and Henry Wagner and Margaret Grunnet and Robins, {H. Ian} and Daniel Karp and Patrick Flynn and George Adams",

year = "1998",

month = feb,

day = "25",

doi = "10.1023/A:1005867520788",

language = "English (US)",

volume = "37",

pages = "55--62",

journal = "Journal of Neuro-Oncology",

issn = "0167-594X",

publisher = "Kluwer Academic Publishers",

number = "1",

}

Hellman, R, Neuberg, DS, Wagner, H, Grunnet, M, Robins, HI, Karp, D, Flynn, P & Adams, G 1998, 'A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group Study (E2392)', Journal of neuro-oncology, vol. 37, no. 1, pp. 55-62. https://doi.org/10.1023/A:1005867520788

A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group Study (E2392). / Hellman, Richard; Neuberg, Donna S.; Wagner, Henry; Grunnet, Margaret; Robins, H. Ian; Karp, Daniel; Flynn, Patrick; Adams, George.

In: Journal of neuro-oncology, Vol. 37, No. 1, 25.02.1998, p. 55-62.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas - An Eastern Cooperative Oncology Group Study (E2392)

AU - Hellman, Richard

AU - Neuberg, Donna S.

AU - Wagner, Henry

AU - Grunnet, Margaret

AU - Robins, H. Ian

AU - Karp, Daniel

AU - Flynn, Patrick

AU - Adams, George

PY - 1998/2/25

Y1 - 1998/2/25

N2 - This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas. Thirty three patients (median age 51 years) were entered (27 with glioblastoma multiforme, 6 with anaplastic astrocytoma). Toxicity was manageable with no lethal toxicities. Five of seven life threatening toxicities were hematologic. Median overall survival was 14.2 months. These data suggest this regimen is effective treatment for patients with high grade gliomas.

AB - This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas. Thirty three patients (median age 51 years) were entered (27 with glioblastoma multiforme, 6 with anaplastic astrocytoma). Toxicity was manageable with no lethal toxicities. Five of seven life threatening toxicities were hematologic. Median overall survival was 14.2 months. These data suggest this regimen is effective treatment for patients with high grade gliomas.

UR - http://www.scopus.com/inward/record.url?scp=0031882420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031882420&partnerID=8YFLogxK

U2 - 10.1023/A:1005867520788

DO - 10.1023/A:1005867520788

M3 - Article

C2 - 9525838

AN - SCOPUS:0031882420

VL - 37

SP - 55

EP - 62

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -